<DOC>
	<DOCNO>NCT00145561</DOCNO>
	<brief_summary>Pharmacokinetic study Saquinavir Ritonavir HIV-infected pregnant woman</brief_summary>
	<brief_title>The Pharmacokinetic Study Saquinavir New Tablet Formulation HIV-Infected Pregnant Women .</brief_title>
	<detailed_description>It generally accept HIV-infected pregnant woman receive treatment prevent transmission HIV mother-to-child.The ( relative ) contra-indications NNRTIs pregnancy make PI base regimen rational choice . Based several experience investigation expect saquinavir play role component tripe drug regimens HIV-infected pregnant woman . Since bid dose regimen 1,000mg saquinavir 100mg ritonavir approve regulatory authority availability new 500mg tablet formulation saquinavir , need well-designed pharmacokinetic trial use new 500mg saquinavir tablet formulation mention dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>HIV infect woman 18 40 year age able willing sign Informed Consent pregnant maximum 31 week history sensitivity/idiosyncrasy drug relevant history interference drug metabolism inability understand trial procedure abnormal specific serum level use specific concomitant medication active hepatobiliary hepatic disease previous failure saquinavir/ritonavir regimen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HIV</keyword>
</DOC>